NCT04957160 (CARINA) is a clinical trial in Advanced Renal Cell Carcinoma (aRCC), sponsored by Ipsen.

Who is sponsoring NCT04957160?

NCT04957160 is sponsored by Ipsen.

What condition does NCT04957160 study?

NCT04957160 studies Advanced Renal Cell Carcinoma (aRCC).

Is NCT04957160 still recruiting?

NCT04957160 is currently completed. Last updated 17 December 2024.

Last reviewed 2024-12-17 · How we verify

NCT04957160: CARINA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination

Completed Last updated 17 December 2024

What this trial tests

trial in Advanced Renal Cell Carcinoma (aRCC) in 281 participants. Completed in 15 June 2022.

Timeline

9 September 2021

Primary endpoint
15 June 2022

15 June 2022

Quick facts

Lead sponsor	Ipsen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	281
Start date	9 September 2021
Primary completion	15 June 2022
Estimated completion	15 June 2022
Sites	9 locations across United Kingdom

Conditions studied

Advanced Renal Cell Carcinoma (aRCC) — all drugs for Advanced Renal Cell Carcinoma (aRCC) →

Sponsor

Ipsen — full company profile →

Who can join

18 and older, any sex, with Advanced Renal Cell Carcinoma (aRCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will collect real-world data for the new treatment pathways for all patients with Advanced Renal Cell Carcinoma (ARCC) who were treated with a 1L IO (first-line, Immuno-Oncology checkpoint inhibitor) combination therapy and progressed to a 2L treatment with particular focus to understanding where cabozantinib is prescribed after 1L IO containing combination therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results.
Nathan P, Venugopal B, Ali J, Allison J, et al · · 2024 · cited 3× · PMID 39107157 · DOI 10.1016/j.clgc.2024.102141

Verify or expand the search:

Other Ipsen trials

Trials by the same sponsor.

NCT07387549 — A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis · Phase 3 · not yet recruiting
NCT07497724 — Retrospective Observational Study of Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-P · not yet recruiting
NCT07427797 — A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between · Phase 3 · recruiting
NCT07435428 — A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Line · Phase 3 · recruiting
NCT07441707 — A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04957160 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ipsen
Last refreshed: 17 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04957160.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing